ClearRead CT
Cardiothoracic AI suite for pulmonary nodule detection and coronary artery calcification scoring
Software · Cloud SaaSCompany source
Company profile
About RIVERAIN MEDICAL GROUP
Riverain Technologies (also known as Riverain Medical Group) is a medical imaging AI company specializing in cardiothoracic imaging solutions. The company develops the ClearRead Chest suite, an advanced AI platform designed to streamline diagnostic workflows for chest CT and X-ray examinations. With over 400 customer locations globally processing millions of exams annually, Riverain maintains a 95% customer retention rate. The company's flagship products include ClearRead CT, a cardiothoracic AI suite for pulmonary nodule detection and coronary artery calcification (CAC) scoring, and ClearRead Xray, a patented solution for chest imaging with tools for pulmonary nodule and pneumothorax detection. These solutions target the leading causes of death globally: lung cancer and cardiovascular disease. The technology is built on advanced AI algorithms that reduce cognitive burden on radiologists while improving detection accuracy and reading efficiency. Riverain's solutions are deployed through both direct sales and a substantial network of global channel partners, including AI platforms, orchestrators, modality manufacturers, and RIS companies. The company serves major healthcare organizations worldwide, including Duke University Medical Center, University Hospital of Zurich, Jefferson Einstein Medical Center, and University of Colorado Hospital. Their technology supports both dedicated lung cancer screening programs and opportunistic screening for incidental findings, with particular emphasis on population health approaches to early detection of cardiothoracic conditions.
Company description RIVERAIN MEDICAL GROUP official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at RIVERAIN MEDICAL GROUP?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiovascular disease
- COPD
- Coronary artery calcification (CAC)
- Emphysema
- Lung cancer
- Pneumothorax
- Pulmonary nodules
Who it serves
- Academic Medical Centers
- Health Systems
- Hospitals
- Imaging Centers
- Radiology Practices
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: AI platforms and orchestrators, Modality manufacturers, Multiple CT scanner manufacturers, PACS systems, RIS systems.
Geographic context
MarketsGlobal (400+ locations worldwide) · United States
Company sourceOfficial website
Company milestones
Platform expansion
New Medicare reimbursement code G0680 for AI-powered CAC scoring on routine chest CT scans announced. Millions of exams processed annually across 400+ customer locations.
Partnerships
Recorded partners
- Channel partners shown in partner logos (specific names not clearly readable in scraped text)
- Modality manufacturers
- Multiple AI platform partners
- PACS vendors
- RIS companies
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ClearRead CT CAC
AI-powered coronary artery calcification scoring for ungated CT exams
Software · Cloud SaaSCompany source
ClearRead CT LTA
Research-use lung tissue analysis tool
Software · HybridCompany source
ClearRead Xray
Patented chest X-ray solution for pulmonary nodule and pneumothorax detection
Software · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
DELTAVIEW MODEL 2.1K111776 · 510k · Dec 28, 2011
RAPIDSCREEN RS-2000P000041 · Pma · Jul 12, 2001
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
95% customer retention rate
Overall customer satisfaction
Improved detection accuracy
Pulmonary nodule and CAC detection
Reduced reading time
Radiologist workflow efficiency
Reduced cognitive burden
Radiologist workload
Lung cancer 5-year survival improves from 12% to 67%
When detected early vs late stage
Half of lung cancers found on follow-up scan
NLST study - importance of early detection
30-40% of lung cancer screening participants may have undiagnosed emphysema/COPD
Opportunistic screening value
Duke University Medical Center
Network-wide deployment of ClearRead CT across leading academic thoracic imaging institution
ClearRead CT software deployed throughout entire Duke University Medical Center network
Jefferson Einstein Medical Center
Multi-site CT scan processing across 13 CT scanners regardless of manufacturer
Seamless processing of CT scans from all 13 CT scanners across different manufacturers and protocols
Regional Medical Imaging
Lung cancer screening program implementation for faster and more accurate CT scan readings
ClearRead CT software used for all CT scans in lung cancer screening program
University Hospital of Zurich
Clinical validation study of ClearRead CT for detection rate and reading time improvements
Significant advantages in detection rate and reading time confirmed through clinical study
University of Colorado Hospital
Implementation of ClearRead Xray technology at top-ranked Colorado hospital
ClearRead Xray technology implemented at hospital named best in Colorado by U.S. News and World Report
University of Maryland Medical Center
Network-wide deployment of cost-effective ClearRead CT across multiple CT manufacturers
Background processing without workflow interruption, consistent care across all patients regardless of CT manufacturer
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Charles White
Professor of Radiology & Vice President of Clinical Affairs
Thomas Frauenfelder
Professor
Jonathan Chung
MD
James Hillis
Director of Clinical Operations
06 · Company updates
Updates from RIVERAIN MEDICAL GROUP
Recent articles published on RIVERAIN MEDICAL GROUP's official website.
European Society of Thoracic Imaging (ESTI)
Read on RIVERAIN MEDICAL GROUPNew Medicare Code G0680 Creates a New Pathway to Generate Revenue for Coronary Artery Calcification (CAC)
Read on RIVERAIN MEDICAL GROUPdeepc Enriches Enterprise Health AI Portfolio with Riverain Technologies’ ClearRead™ solutions on deepcOS®
Read on RIVERAIN MEDICAL GROUPChest
Read on RIVERAIN MEDICAL GROUPVIDA Partners with Riverain Technologies to Extend Best-of-Breed AI Imaging for Life Sciences
Read on RIVERAIN MEDICAL GROUP07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.